Status:
COMPLETED
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
Lead Sponsor:
University of Chicago
Conditions:
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Eligibility:
All Genders
10+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.
Eligibility Criteria
Inclusion
- Patients must have received cytotoxic chemotherapy,radiation,or a drug known to affect the properties of DNA or cell growth for some condition other than acute myeloid leukemia prior to diagnosis.
- Patients must have t-MDS/t-AML
- To be eligible for allogeneic transplantation, patients must have a suitable donor who is HLA compatible.
- Patients must be over the age of 10.
- Patients must be reviewed and discussed at the Leukemia and Transplant Conferences of the Section of Hematology/Oncology.
Exclusion
- Patients must not have any other serious medical condition(e.g.uncontrolled or severe cardiovascular disease, diabetes, pulmonary disease, or infection)
- Psychiatric condition which would prevent compliance or possibly be worsened by treatment
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00774046
Start Date
December 1 2002
End Date
March 1 2011
Last Update
February 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637